Bedinvetmab (anti-NGF monoclonal antibody)
Sold as Librela, Beransa
A monthly injection that blocks a pain-signaling protein. It genuinely relieves arthritis pain in a substantial minority of dogs and avoids the gut and kidney risks of NSAIDs, but it is not reversible once injected and its long-term joint safety is actively debated.
Why this grade
Multiple randomized, placebo- and active-controlled trials show a real analgesic effect, and the pivotal trial was properly blinded and placebo-controlled. It is held at B rather than A because the placebo-adjusted response rate is moderate (43.5% vs 16.9% at day 28), the head-to-head comparison against meloxicam did not reach statistical significance for superiority, and an unresolved post-marketing safety signal around rapidly progressive osteoarthritis is under active discussion in the peer-reviewed literature.
What the trials show
In the pivotal double-blind, placebo-controlled multisite trial, 43.5% of bedinvetmab-treated dogs met the predefined treatment-success threshold at day 28 versus 16.9% on placebo. That is a placebo-adjusted benefit of roughly 27 percentage points, meaning about one in four treated dogs improves because of the drug rather than because of time, attention, and owner expectation. In a randomized open-label comparison against meloxicam, both groups improved significantly from baseline on the Canine Orthopaedic Index; bedinvetmab's larger mean reduction was not statistically significant, so the honest reading is comparable efficacy with a different side-effect profile: 4 adverse events on bedinvetmab versus 17 on meloxicam, 9 of them gastrointestinal. A separate randomized non-inferiority trial using force-plate gait analysis compared it against grapiprant in a small cohort of 32 dogs.
Harms and cautions
Injection-site reactions, and reports of neurological and mobility-related adverse events in post-marketing surveillance. The most serious open question is rapidly progressive osteoarthritis, meaning accelerated joint destruction of the kind seen with anti-NGF drugs in human trials, which halted their human development. A 2026 JAVMA paper argues this signal warrants vigilant adverse event reporting in dogs. Because the antibody persists for weeks, an adverse reaction cannot be stopped by discontinuing a daily pill. Discuss this openly rather than treating approval as settled reassurance.
Practical detail
- Route
- Subcutaneous injection given in-clinic
- Typical course
- Once monthly; effect is assessed over 2-3 cycles
- Monitoring
- Baseline orthopedic exam, owner-completed pain score before starting and at each visit, and prompt reporting of any new limb weakness or sudden worsening
- Cost
- high
Regulatory status
- United States
- FDA-approved (2023) for control of osteoarthritis pain in dogs.
- European Union
- EMA-authorized since 2020 as Librela.
- Note
- Approval means the regulator accepted the efficacy and safety package. It is not a claim that the drug is the best option for a given dog.
Questions worth asking your vet
- Has my dog been screened for the joint instability or neurological signs that would make me more cautious about anti-NGF treatment?
- What specific pain score are we measuring, and what change would count as this having failed?
- If we see accelerated joint damage, what is the plan given the drug cannot be withdrawn quickly?
- Would an NSAID trial be reasonable first for my dog, given their kidney and GI history?
The evidence, one study at a time
Corral MJ, Moyaert H, Fernandes T, Escalada M, Tena JKS, Walters RR, Stegemann MR. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia, 2021;48(6):943-955.
rct 2021
The pivotal registration trial. Well designed, properly blinded, and placebo controlled across 26 practices. The effect is real but moderate, and the study was designed, run, and written by the manufacturer.
- Design
- Prospective, randomized, blinded, placebo-controlled, multisite
- Dogs analyzed
- 287
- Blinding
- double-blind
- Control
- Placebo
- Duration
- 28 days to primary endpoint
- Population
- 287 client-owned dogs with osteoarthritis across 26 veterinary practices in four countries
- Primary outcome
- Owner-assessed treatment success on the Canine Brief Pain Inventory
- Result
- 43.5% treatment success with bedinvetmab versus 16.9% with placebo at day 28.
- Funding
- Zoetis. The authors were Zoetis employees in Belgium and the United States.
A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. 2025.
rct 2025
Suggests comparable pain control to a standard NSAID with fewer gastrointestinal events, but the lack of blinding inflates confidence in owner-reported outcomes.
- Design
- Randomized, open-label, multicentre, parallel-group active comparator
- Blinding
- open-label
- Control
- Meloxicam (active comparator)
- Duration
- Multi-week
- Population
- Client-owned dogs with osteoarthritis-related pain
- Primary outcome
- Change in Canine Orthopaedic Index score
- Result
- Both groups improved significantly from baseline; bedinvetmab's larger mean reduction was not statistically significant. Adverse events: 4 (bedinvetmab) versus 17 (meloxicam), including 9 gastrointestinal events on meloxicam.
- Funding
- Disclosed in source publication; open-label design is a meaningful limitation
A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis. Scientific Reports, 2026.
rct 2026
Valuable because force-plate analysis sidesteps the large placebo effect that contaminates owner-reported canine pain outcomes. Small sample limits precision.
- Design
- Randomized, double-blind, non-inferiority
- Dogs analyzed
- 32
- Blinding
- double-blind
- Control
- Grapiprant (active comparator)
- Duration
- Reported in source
- Population
- Dogs with osteoarthritis
- Primary outcome
- Objective force-plate gait analysis
- Result
- Compared bedinvetmab against grapiprant using an objective rather than owner-reported endpoint.
- Funding
- See publication
Bedinvetmab (Librela/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting. Journal of the American Veterinary Medical Association, 2026.
safety report 2026
The most important counterweight to the registration trials. Read this before assuming approval settles the safety question.
- Design
- Commentary and pharmacovigilance analysis
- Blinding
- not-applicable
- Result
- Argues that post-marketing reports, including rapidly progressive osteoarthritis, justify heightened surveillance and franker owner consent discussions.